The BH3-mimetic obatoclax reduces HIF-1α levels and HIF-1 transcriptional activity and sensitizes hypoxic colon adenocarcinoma cells to 5-fluorouracil

Cancer Letters

Volumn 364, Issue 2, 2015, Pages 156-164

  Gariboldi, Marzia B ^a   Taiana, Elisa ^a   Bonzi, Maria Chiara ^a   Craparotta, Ilaria ^a   Giovannardi, Stefano ^a   Mancini, Monica ^a   Monti, Elena ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

5 Fluorouracil; Colon cancer; Drug resistance; HIF 1; Obatoclax; Oxaliplatin

Indexed keywords

FLUOROURACIL; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; OBATOCLAX; OXALIPLATIN; ANTINEOPLASTIC AGENT; HIF1A PROTEIN, HUMAN; PYRROLE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL; CELL CYCLE ARREST; CHEMOSENSITIZATION; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; ADENOCARCINOMA; CELL HYPOXIA; CELL PROLIFERATION; COLONIC NEOPLASMS; DOWN REGULATION; DRUG EFFECTS; DRUG POTENTIATION; GENETICS; HCT116 CELL LINE; HT 29 CELL LINE; METABOLISM; PATHOLOGY; TRANSCRIPTION INITIATION;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL HYPOXIA; CELL PROLIFERATION; COLONIC NEOPLASMS; DOWN-REGULATION; DRUG SYNERGISM; FLUOROURACIL; HCT116 CELLS; HT29 CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; PYRROLES; TRANSCRIPTIONAL ACTIVATION;

EID: 84930082574     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.05.008     Document Type: Article

References (47)

1. Cosse J., Michiels C. Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression. Anticancer Agents Med. Chem 2008, 8:790-797.
2. Vaupel P., Thews O., Hoeckel M. Treatment resistance of solid tumors: role of hypoxia and anemia. Med. Oncol 2001, 18:243-259.
3. Semenza G. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 2003, 3:721-732.
4. Semenza G. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010, 29:625-634.
5. Rohwer N., Cramer T. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist. Updat 2011, 14:191-201.
6. Ravizza R., Molteni R., Gariboldi M.B., Marras E., Perletti G., Monti E. Effect of HIF-1 modulation on the response of two- and three-dimensional cultures of human colon cancer cells to 5-fluorouracil. Eur. J. Cancer 2009, 45:890-898.
7. Mayes P.A., Dolloff N.G., Daniel C.J., Liu J.J., Hart L.S., Kuribayashi K., et al. Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3β and CDK1. Cancer Res 2011, 71:5265-5275.
8. Monti E., Gariboldi M.B. HIF-1 as a target for cancer chemotherapy, chemosensitization and chemoprevention. Curr. Mol. Pharmacol 2011, 4:62-77.
9. Comerford K., Wallace T., Karhausen J., Louis N., Montalto M., Colgan S. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 2002, 62:3387-3394.
10. Krishnamurthy P., Ross D., Nakanishi T., Bailey-Dell K., Zhou S., Mercer K., et al. The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J. Biol. Chem 2004, 279:24218-24225.
11. Koshiji M., To K., Hammer S., Kumamoto K., Harris A., Modrich P., et al. HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expression. Mol. Cell 2005, 17:793-803.
12. Chen N., Chen X., Huang R., Zeng H., Gong J., Meng W., et al. BCL-xL is a target gene regulated by hypoxia-inducible factor-1{alpha}. J. Biol. Chem 2009, 284:10004-10012.
13. Piret J., Minet E., Cosse J., Ninane N., Debacq C., Raes M., et al. Hypoxia-inducible factor-1-dependent overexpression of myeloid cell factor-1 protects hypoxic cells against tert-butyl hydroperoxide-induced apoptosis. J. Biol. Chem 2005, 280:9336-9344.
14. Flamant L., Notte A., Ninane N., Raes M., Michiels C. Anti-apoptotic role of HIF-1 and AP-1 in paclitaxel exposed breast cancer cells under hypoxia. Mol. Cancer 2010, 9:191.
15. Erler J., Cawthorne C., Williams K., Koritzinsky M., Wouters B., Wilson C., et al. Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol. Cell. Biol 2004, 24:2875-2889.
16. Cragg M.S., Harris C., Strasser A., Scott C.L. Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics. Nat. Rev. Cancer 2009, 9:321-326.
17. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat. Rev. Cancer 2012, 12:159-169.
18. Lessene G., Czabotar P.E., Colman P.M. BCL-2 family antagonists for cancer therapy. Nat. Rev. Drug Discov 2008, 7:989-1000.
19. Nguyen M., Marcellus R.C., Roulston A., Watson M., Serfass L., Murthy Madiraju S.R., et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:19512-19517.
20. Acoca S., Cui Q., Shore G.C., Purisima E.O. Molecular dynamics study of small molecule inhibitors of the Bcl-2 family. Proteins 2011, 79:2624-2636.
21. Zhai D., Jin C., Satterthwait A.C., Reed J.C. Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins. Cell Death Differ 2006, 13:1419-1421.
22. Shore G.C., Viallet J. Modulating the bcl-2 family of apoptosis suppressors for potential therapeutic benefit in cancer. Hematology Am. Soc. Hematol. Educ. Program 2005, 226-230.
23. Jóna A., Khaskhely N., Buglio D., Shafer J.A., Derenzini E., Bollard C.M., et al. The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis inHodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors. Exp. Hematol 2011, 39:1007-1017. e1001.
24. Dasmahapatra G., Lembersky D., Son M.P., Patel H., Peterson D., Attkisson E., et al. Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo. Mol. Cancer Ther 2012, 11:1122-1132.
25. Pan J., Cheng C., Verstovsek S., Chen Q., Jin Y., Cao Q. The BH3-mimetic GX15-070 induces autophagy, potentiates the cytotoxicity of carboplatin and 5-fluorouracil in esophageal carcinoma cells. Cancer Lett 2010, 293:167-174.
26. Cruickshanks N., Hamed H.A., Bareford M.D., Poklepovic A., Fisher P.B., Grant S., et al. Lapatinib and obatoclax kill tumor cells through blockade of ERBB1/3/4 and through inhibition of BCL-XL and MCL-1. Mol. Pharmacol 2012, 81:748-758.
27. Li J., Viallet J., Haura E.B. A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells. Cancer Chemother. Pharmacol 2008, 61:525-534.
28. Witters L.M., Witkoski A., Planas-Silva M.D., Berger M., Viallet J., Lipton A. Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor. Oncol. Rep 2007, 17:465-469.
29. Rahmani M., Aust M.M., Attkisson E., Williams D.C., Ferreira-Gonzalez A., Grant S. Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process. Blood 2012, 119:6089-6098.
30. Yuan Y., Hilliard G., Ferguson T., Millhorn D. Cobalt inhibits the interaction between hypoxia-inducible factor-alpha and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-alpha. J. Biol. Chem 2003, 278:15911-15916.
31. Gariboldi M., Ravizza R., Molteni R., Osella D., Gabano E., Monti E. Inhibition of Stat3 increases doxorubicin sensitivity in a human metastatic breast cancer cell line. Cancer Lett 2007, 258:181-188.
32. Schimmer A.D., O'Brien S., Kantarjian H., Brandwein J., Cheson B.D., Minden M.D., et al. A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin. Cancer Res 2008, 14:8295-8301.
33. Moeller B.J., Cao Y., Li C.Y., Dewhirst M.W. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 2004, 5:429-441.
34. Masson N., Willam C., Maxwell P.H., Pugh C.W., Ratcliffe P.J. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J. 2001, 20:5197-5206.
35. Lu X., Kang Y. Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin. Cancer Res 2010, 16:5928-5935.
36. Adamski J., Price A., Dive C., Makin G. Hypoxia-induced cytotoxic drug resistance in osteosarcoma is independent of HIF-1alpha. PLoS ONE 2013, 8:e65304.
37. Klymenko T., Brandenburg M., Morrow C., Dive C., Makin G. The novel Bcl-2 inhibitor ABT-737 is more effective in hypoxia and is able to reverse hypoxia-induced drug resistance in neuroblastoma cells. Mol. Cancer Ther 2011, 10:2373-2383.
38. Harrison L.R., Micha D., Brandenburg M., Simpson K.L., Morrow C.J., Denneny O., et al. Hypoxic human cancer cells are sensitized to BH-3 mimetic-induced apoptosis via downregulation of the Bcl-2 protein Mcl-1. J. Clin. Invest 2011, 121:1075-1087.
39. Müller A., Zang C., Chumduri C., Dörken B., Daniel P.T., Scholz C.W. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma. Int. J. Cancer 2013, 133:1813-1824.
40. Peter B., Cerny-Reiterer S., Hadzijusufovic E., Schuch K., Stefanzl G., Eisenwort G., et al. The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells. J. Leukoc. Biol 2014, 95:95-104.
41. Konopleva M., Watt J., Contractor R., Tsao T., Harris D., Estrov Z., et al. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res 2008, 68:3413-3420.
42. Vogler M., Weber K., Dinsdale D., Schmitz I., Schulze-Osthoff K., Dyer M.J., et al. Different forms of cell death induced by putative BCL2 inhibitors. Cell Death Differ 2009, 16:1030-1039.
43. Espona-Fiedler M., Soto-Cerrato V., Hosseini A., Lizcano J.M., Guallar V., Quesada R., et al. Identification of dual mTORC1 and mTORC2 inhibitors in melanoma cells: prodigiosin vs. obatoclax. Biochem. Pharmacol 2012, 83:489-496.
44. Tang Y., Hamed H.A., Cruickshanks N., Fisher P.B., Grant S., Dent P. Obatoclax and lapatinib interact to induce toxic autophagy through NOXA. Mol. Pharmacol 2012, 81:527-540.
45. Koehler B.C., Scherr A.L., Lorenz S., Elssner C., Kautz N., Welte S., et al. Pan-Bcl-2 inhibitor obatoclax delays cell cycle progression and blocks migration of colorectal cancer cells. PLoS ONE 2014, 9:e106571.
46. Kong X., Alvarez-Castelao B., Lin Z., Castaño J., Caro J. Constitutive/hypoxic degradation of HIF-alpha proteins by the proteasome is independent of von Hippel Lindau protein ubiquitylation and the transactivation activity of the protein. J. Biol. Chem 2007, 282:15498-15505.
47. Yee Koh M., Spivak-Kroizman T., Powis G. HIF-1 regulation: not so easy come, easy go. Trends Biochem. Sci 2008, 33:526-534.